Literature DB >> 10602889

The role of monocytes and natural killer cells in mediating antibody-dependent lysis of colorectal tumour cells.

N Abdullah1, J Greenman, A Pimenidou, K P Topping, J R Monson.   

Abstract

Monocytes and natural killer (NK) cells are known to be important effector cell populations in mediating antibody-dependent cell-mediated cytotoxicity (ADCC). Purified monocyte and NK effector cell populations, from normal and colorectal cancer (CRC) patients, together with a number of murine (17-1A and 323/A3) and their chimaeric (c17-1A) or humanised (3622W94) equivalents, and chimaeric (c) SF25 were compared for their ability to mediate ADCC of colorectal tumour cells. The chimaeric and humanised antibodies were significantly better at mediating tumour lysis than their murine equivalents with all-effector populations. When effector cells from CRC patients were used the cSF25 antibody was significantly better than 3622W94 (P < 0.02) which, in turn, was significantly better than c17-1A (P < 0.03). Depletion of NK cells produced a decrease in specific tumour lysis with all antibodies. In addition a higher rate of NK cell death was observed in CRC patients during the assay than in normal controls. The chimaeric and humanised antibodies stained a similar percentage of the HT-29 target cells (>80%), but 3622W94 bound to significantly more cells from primary tumour biopsies than cSF-25 (P = 0.001). Together, the results suggest that NK cells are the most important effector cell type mediating ADCC in vitro, that there is some impairment of NK function in CRC patients, and that cSF25 is the most potent antibody. For use in vivo the anti-Ep-CAM antibody 3622W94 would appear to be the most suitable reagent for further study.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10602889     DOI: 10.1007/s002620050600

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  7 in total

1.  A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.

Authors:  Randall J Brezski; Michelle Kinder; Katharine D Grugan; Keri L Soring; Jill Carton; Allison R Greenplate; Theodore Petley; Dorie Capaldi; Kerry Brosnan; Eva Emmell; Sharon Watson; Robert E Jordan
Journal:  MAbs       Date:  2014-10-30       Impact factor: 5.857

Review 2.  Mechanisms involved in antibody- and complement-mediated allograft rejection.

Authors:  Barbara A Wasowska
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

3.  Cytotoxic activity of novel human monoclonal antibody MT201 against primary ovarian tumor cells.

Authors:  Wei Xiang; Pauline Wimberger; Torsten Dreier; Joachim Diebold; Doris Mayr; Patrick A Baeuerle; Rainer Kimmig
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-18       Impact factor: 4.553

4.  In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule.

Authors:  W Steve Ammons; Robert J Bauer; Arnold H Horwitz; Zhi J Chen; Eddie Bautista; Harry H Ruan; Marina Abramova; Kristen R Scott; Russell L Dedrick
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

5.  A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy.

Authors:  Xuejun Fan; Randall J Brezski; Ming Fa; Hui Deng; Allison Oberholtzer; Anneliese Gonzalez; William P Dubinsky; William R Strohl; Robert E Jordan; Ningyan Zhang; Zhiqiang An
Journal:  Breast Cancer Res       Date:  2012-08-08       Impact factor: 6.466

6.  Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.

Authors:  P Went; M Vasei; L Bubendorf; L Terracciano; L Tornillo; U Riede; J Kononen; R Simon; G Sauter; P A Baeuerle
Journal:  Br J Cancer       Date:  2006-01-16       Impact factor: 7.640

7.  Combination of NK Cells and Cetuximab to Enhance Anti-Tumor Responses in RAS Mutant Metastatic Colorectal Cancer.

Authors:  John Pradeep Veluchamy; Jan Spanholtz; Marleen Tordoir; Victor L Thijssen; Daniëlle A M Heideman; Henk M W Verheul; Tanja D de Gruijl; Hans J van der Vliet
Journal:  PLoS One       Date:  2016-06-17       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.